Spark Therapeutics, Inc. Common Stock
ONCE
ONCE was delisted on the 16th of December, 2019.
194 hedge funds and large institutions have $3.6B invested in Spark Therapeutics, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 43 funds opening new positions, 66 increasing their positions, 58 reducing their positions, and 45 closing their positions.
14% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 58
9% more call options, than puts
Call options by funds: $76.4M | Put options by funds: $70.2M
4% less first-time investments, than exits
New positions opened: 43 | Existing positions closed: 45
3% less funds holding
Funds holding: 199 → 194 (-5)
9% less funds holding in top 10
Funds holding in top 10: 22 → 20 (-2)
11% less capital invested
Capital invested by funds: $4.04B → $3.6B (-$436M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$84.2M |
| 2 |
PC
Paulson & Co
New York
|
+$81.8M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
+$64.7M |
| 4 |
TAL
TIG Advisors LLC
New York
|
+$64.6M |
| 5 |
Renaissance Technologies
New York
|
+$42.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$138M |
| 2 |
BCM
Beryl Capital Management
Redondo Beach,
California
|
-$102M |
| 3 |
Goldman Sachs
New York
|
-$62.6M |
| 4 |
SCS
Syquant Capital SAS
Paris,
France
|
-$58.2M |
| 5 |
WIC
Water Island Capital
New York
|
-$58M |
ONCE Hedge Fund Activity: Q2 2019 in Review
194 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Spark Therapeutics, Inc. Common Stock (ONCE) for Q2 2019, worth a combined $3.6B — down 11% from $4.04B a quarter earlier.
Sellers outnumbered buyers: 45 funds closed out of ONCE and 43 opened new positions — a net loss of 2 holders — while 58 trimmed existing stakes and 66 added.
The largest buyer was Pentwater Capital Management, opening a new position worth an estimated $84.2M. The largest seller was Federated Hermes, cutting an estimated $138M.
- 194 institutional investors held Spark Therapeutics, Inc. Common Stock (ONCE) as of Q2 2019, down from 199 in Q1 2019.
- Funds reported $3.6B of Spark Therapeutics, Inc. Common Stock stock for Q2 2019, down 11% quarter-over-quarter.
- 43 funds opened new Spark Therapeutics, Inc. Common Stock positions in Q2 2019 and 45 closed out, a net change of -2 holders.
- The largest Spark Therapeutics, Inc. Common Stock buyer in Q2 2019 was Pentwater Capital Management, an estimated $84.2M added.
- The largest Spark Therapeutics, Inc. Common Stock seller in Q2 2019 was Federated Hermes, an estimated $138M sold.
Based on aggregated 13F filings for Q2 2019.